Sublingual specific immunotherapy for adults and children: a post-marketing surveillance study

Drachenberg, K. J.; Urbán, Edit; Proll, Sean; Woroniecki, Stefan R.

doi:10.1016/s0301-0546(04)79231-9

Cited by 17 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four weeks before the onset of dysphagia, the patient had begun SLIT with ORALVAC Compact (Bencard Allergie GmbH, Munich, Germany), a commercially available treatment considered to be safe [4]. The SLIT contained specific soluble allergens (hazelnut, birch, alder) according to previous specific serum IgE testing, administered sublingually as prescribed by the manufacturer's instructions.…”

Section: Case Reportmentioning

confidence: 99%

Induction of Eosinophilic Esophagitis by Sublingual Pollen Immunotherapy

Miehlke

Alpan

Schröder³

et al. 2013

Case Rep Gastroenterol

117

View full text Add to dashboard Cite

Sublingual immunotherapy (SLIT) is increasingly investigated and utilized for the treatment of food and pollen allergies. Previous case reports suggested that eosinophilic esophagitis (EoE) might develop as a long-term complication in children after completion of oral immunotherapy. Here, we describe a 44-year-old female with a medical history of pollinosis who for the first time in her life developed complete manifestation of EoE (peak eosinophils 164/high power field) 4 weeks after initiation of SLIT using specific soluble allergens (hazelnut, birch, alder) according to previous specific serum IgE testing. After discontinuation of SLIT, EoE resolved completely within 4 weeks without any other medical intervention. During a follow-up of 12 months the patient remained free of any esophageal symptoms. This is the first case report demonstrating a close and therefore likely causative association between pollen SLIT and EoE in an adult patient.

show abstract

Section: Case Reportmentioning

confidence: 99%

Induction of Eosinophilic Esophagitis by Sublingual Pollen Immunotherapy

Miehlke

Alpan

Schröder³

et al. 2013

Case Rep Gastroenterol

117

View full text Add to dashboard Cite

show abstract

“…Overall prevalence of systemic adverse events was lower than 20% in DB-PC-RCT, whereas the prevalence of severe systemic reactions was between 1 and 2% of total recorded events [88][89][90][91][92][93]. Most commonly postmarketing surveys reported mild to moderate usually self-resolved systemic reactions [94,95].…”

Section: Safety and Tolerability Of Slit In Allergic Childrenmentioning

confidence: 99%

“…Although previous systemic reaction due to SCIT were considered as absolute contraindication for all kinds of immunotherapy, results from recent studies showed that they do not represent risk factors for further usage of other kinds of ASIT including sublingual [96]. Local adverse reactions are most common SLIT-related side effects although it is not very easy to record them as it is not usually including in postmarketing analysis nor in DB-PC-RCT [50,[85][86][87][88]. Its prevalence varies from 50 to 80% and they include oropharyngeal and gastrointestinal reactions such as itching, pruritus, and eczema in oral mucosa and/or diarrhoea, vomitus, and abdominal pain [97][98][99].…”

Section: Safety and Tolerability Of Slit In Allergic Childrenmentioning

confidence: 99%

Current Issues on Immunotherapy in Children

Djuric-Filipovic¹,

Živanović²,

Kostić³

et al. 2017

Allergen

View full text Add to dashboard Cite

Therapy of allergic diseases in children implicates avoidance of allergens, standard pharmacotherapy, and immunotherapy. Immunotherapy is the only treatment for allergic diseases with the ability to change the natural course of the disease, thus stopping its further progression as well as the development of new allergic diseases and new sensibilizations. The objective of this chapter is to give insight into the latest data on immunotherapy in treating children with allergic diseases. Methods: The study involved a search for relevant articles on the MEDLINE and PubMed up to 2017. Results: Numerous studies have shown that the sublingual application of allergen-specific immunotherapy is adequate, safe, and efficient in the therapy of immunoglobulin E (IgE)-mediated allergic diseases of the respiratory tract in children, but there are still some questions to be solved concerning the usage of SLIT in children younger than 5 years old, SLIT for polysensitized patients, duration of SLIT, long-lasting effects of SLIT. Conclusions: In order to improve the clinical efficacy of SLIT, we are looking for new routes of administration, new allergens, new protocols as well as combination of SLIT with other immune modulatory treatments.

show abstract

“…82,83 The adjuvant may be injected with natural allergens or genetically linked with allergen-cDNA. 86 A ragweed-TLR-9 agonist vaccine for IT was also tested in clinical trials in allergic rhinitis patients. IL-12 has also been suggested as an adjuvant for vaccination against diseases in which the Th2 profile predominates.…”

Section: Allergen-specific Therapy With Th1-stimulating Adjuvantsmentioning

confidence: 99%